Psychiatrist.comNext-Step Treatment Options for Treatment-Resistant Depression: Insights From the Mayo Clinic Depression Center Panel

A Mayo Clinic panel of 10 TRD specialists reached strong consensus on next-step treatments after 3 failed antidepressants: augmentation with second-generation antipsychotics, transcranial magnetic stimulation, and ketamine/esketamine. One-third of major depression patients develop treatment resistance, driving increased suicide risk and healthcare costs without standardized treatment selection guidance.

⚖️ PROFESSIONAL IMPACT

• Expert consensus prioritizes augmentation strategies (antipsychotics, TMS, ketamine) over switching antidepressants as fourth-line treatment, challenging sequential monotherapy approaches.
• Patient factors dramatically shift treatment preferences including metabolic disease, age, and clinical complexity requiring individualized selection beyond guideline tier systems.
• Modified Delphi process using real-world vignettes produced actionable treatment algorithms where current guidelines group options broadly without clear prioritization.
• Panel identified persistent evidence gaps particularly for newer interventions like ketamine/esketamine in routine clinical settings with comorbid complexity.

🎯 ACTION ITEMS

• Document 3 prior adequate antidepressant trials before applying TRD next-step protocols.
• Consider augmentation with antipsychotics, TMS, or ketamine/esketamine before switching to fourth antidepressant monotherapy.
• Screen for metabolic disease, age-related factors, and comorbidities that modify treatment selection within consensus framework.
• Integrate patient preferences when choosing among equivalent evidence-based options for treatment-resistant cases.

More on Ketamine